Literature DB >> 8593032

Clarithromycin is inactive against Mycobacterium tuberculosis.

C Truffot-Pernot1, N Lounis, J H Grosset, B Ji.   

Abstract

When 10% oleic acid-albumin-dextrose-catalase-enriched Mueller-Hinton agar medium was employed, the MICs of clarithromycin (CLARI) at which 50 and 90% of 12 strains of Mycobacterium tuberculosis were inhibited were 64 and > 128 micrograms/ml, respectively, which are significantly greater than the achievable peak CLARI concentrations in serum and in lung tissue in humans. In two different mouse experiments, 4 to 6 weeks of treatment with CLARI at 200 mg/kg of body weight six times weekly produced neither bactericidal nor bacteriostatic effects against M. tuberculosis. Therefore, we conclude that CLARI as a single drug is inactive against M. tuberculosis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8593032      PMCID： PMC163042          DOI： 10.1128/AAC.39.12.2827

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 2.  Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.

Authors:  D J Hardy; D R Guay; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

3.  [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].

Authors:  J Grosset; C Truffot; J Fermanian; H Lecoeur
Journal:  Pathol Biol (Paris)       Date:  1982-06

4.  Therapy of multidrug-resistant tuberculosis: lessons from studies with mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

5.  The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans.

Authors:  F Fraschini; F Scaglione; G Pintucci; G Maccarinelli; S Dugnani; G Demartini
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

6.  Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice.

Authors:  B Ji; E G Perani; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

Authors:  L Chapuis; B Ji; C Truffot-Pernot; R J O'Brien; M C Raviglione; J H Grosset
Journal:  Am J Respir Crit Care Med       Date:  1994-11       Impact factor: 21.405

8.  Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.

Authors:  S J Cavalieri; J R Biehle; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

9.  Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.

Authors:  C Truffot-Pernot; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  14 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.

Authors:  Kevin A Nash; Yansheng Zhang; Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Antimicrob Chemother       Date:  2004-12-08       Impact factor: 5.790

3.  Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible.

Authors:  Nadya Andini; Kevin A Nash
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

Authors:  N Mor; A Esfandiari
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 7.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

8.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

9.  Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

Authors:  N Lounis; C Truffot-Pernot; A Bentoucha; J Robert; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Authors:  M S Bolhuis; R van Altena; K van Hateren; W C M de Lange; B Greijdanus; D R A Uges; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.